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Abstract
Background/Aims: Cerebrovascular disease (CeVD) is one of the leading causes of death in 
patients initialising peritoneal dialysis (PD). Currently there is no risk score to predict the future 
risk of CeVD on entry into PD. This study aimed to derive and validate a risk prediction model 
for CeVD mortality in 2 years after the initialisation of PD. Methods: All patients registered 
with the Henan Peritoneal Dialysis Registry (HPDR) between 2007 and 2014 were included. 
Multivariable logistic regression modelling was applied to derive the risk score.  All accessible 
clinical measurements were screened as potential predictors. Internal validation through 
bootstrapping was applied to test the model performance. Results: The absolute risk of CeVD 
mortality was 2.9%. Systolic and diastolic blood pressure, total cholesterol, phosphate, and 
sodium concentrations were the strongest predictors of CeVD mortality in the final risk score. 
Good model discrimination with C statistics above 0.70 and calibration of agreed observed 
and predicted risks were identified in the model. Conclusion: The new risk score, developed 
and validated using clinical measurements that are accessible on entry into PD, could be used 
clinically to screen for patients at high risk of CeVD mortality. Such patients might benefit from 
therapies reducing the incidence of CeVD related events.
IntroductionCardiovascular disease is the leading cause of death in patients with kidney failure treated by dialysis [1, 2]. Although much focus has been on their high rates of myocardial infarction, cardiomyopathy, and cardiac arrhythmia, less attention has been given to 
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the equally debilitating burden of cerebrovascular disease [3, 4]. The high incidence of haemorrhagic and ischemic stroke in individuals receiving hemodialysis (HD) and in those 
undergoing peritoneal dialysis (PD) is a significant concern [5]. In leveraging a country-wide comprehensive medical records system in Taiwan, Wang et al. [6] reported a 2- to 6-fold 
higher risk of stroke in HD and PD patients compared with age- and sex-matched individuals 
from a non-dialysis reference group from the general population. When adjusted for baseline comorbid conditions, HD and PD patients had comparable but much higher hazards for ischemic (2.88 and 3.21, respectively) and haemorrhagic stroke.
In clinical practice, identification of individuals at high risk of cerebrovascular disease can assist the tailoring of more intensive, personalised management to improve patient 
prognosis. For this specific reason, several risk scores have been derived for the prediction 
of cerebrovascular disease in general population [7, 8] and other specific populations, such as those with diabetes [9]. However, there have been no risk scores developed for incident peritoneal dialysis patients to predict their risk of cerebrovascular mortality.Furthermore, unlike the situation in health care systems in many developed countries, a complete medical history is unlikely to be obtained under the health care systems in most developing countries due to limitations in the primary and secondary care systems 
inaccurately recording pre-existing comorbidities [10, 11]. There could be information bias in this setting if the risk algorithm developed depended upon the medical history that was 
self-reported by the patient. There is therefore a need for a risk prediction model that could 
predict future cerebrovascular death, mainly utilising objective clinical measurements likely to be accessible in most developing countries.
The aim of this study was to derive and validate a risk algorithm to predict the 2-year risk of cerebrovascular mortality among incident peritoneal dialysis patients.
Materials and Methods
Data setting and study population
In this study, data from the Henan Peritoneal Dialysis Registry (HPDR) were used to derive and validate 
the risk prediction model. Situated in Central China, Henan is a province with over 100 million population. 
Briefly, the HPDR is administrated under the auspices of the Department of Nephrology, the First Affiliated Hospital of Zhengzhou University which is in charge of an independent audit and analysis of medical care for renal disease in the province [12]. Over the study period, patients’ information was prospectively collected 
electronically from all nephrological departments across the province. All data ma at the HPDR are subjected 
to an algorithm which identifies suspicious measurements, which are then further examined and corrected where necessary by contacting the nephrological department. This study was designed as a cohort study, 
which included all patients aged >= 18 years (n=3,070) who commenced PD between 2007-2014 and who 
had at least 2 years’ follow-up after baseline measurement. Patients who died (n=5), underwent kidney 
transplant (n=9) or whose renal function recovered (n=2) within 90 days after initialisation of dialysis 
were excluded to avoid a reverse causality association between candidate predictors and primary outcome 
(final n=3,054). This reflects the standard approach to investigating “real” ESRD patients among all those initialising PD care.
Ethics approval was granted by the Clinical Research Ethics Committee of the First Affiliated Hospital of Zhengzhou University. Written informed consent was obtained from all participants before inclusion.
Defining outcome, predictors, missing data and power calculation
The primary outcome in the study was defined as recorded death with clinical diagnosis of cerebrovascular disease [13, 14].
All available patients’ information, covering self-reported comorbidities, demographic characteristics, 
and clinical measurements (262 variables) were collected by the time of initialising the PD for review by 5 
clinicians. Variables agreed to be clinically relevant by ≥3 clinicians were included in the analysis for further evaluation as candidate predictors. Backward elimination within a multivariable logistic regression model, 
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with all candidate predictors, was applied to pin down the parameters for the final prediction model.  For 
predictors included in the final model, our cohort had missing information on body mass index (13.51%), 
phosphate (20.92%), albumin (19.92%), total protein (22.57%), total cholesterol (24.25%), low density 
lipoprotein (24.58%), fasting glucose (15.92%), sodium (8.02%), systolic blood pressure (4.82%), and 
diastolic blood pressure (4.82%). Multiple imputation was applied to replace missing values by using a chained equation method based on all candidate predictors and primary outcome to improve the model 
accuracy [15, 16, 17]. 30 imputed datasets were generated for missing predictors that were then combined 
across all datasets by using Rubin’s rule to generate final model estimates [18]. With 89 cerebrovascular 
deaths during the first 2 years of initialising PD and 11 predictors in the final derivation cohort, an effective 
sample size was estimated with 8 final events per predictor, close to the minimum requirement suggested by Peduzzi et al. [19].
Model development and validation
In this study, cerebrovascular mortality within the first 2 years of initialising PD was tackled as a binary 
outcome measure. A univariable logistic regression model was used to estimate the unadjusted odds ratio 
for each candidate parameter. Candidate predictors that were not statistically significant were excluded from the multivariable Logistic regression model by backward elimination (P > 0.1 based on change in log 
likelihood) [20]. Excluded predictors were reinserted into the final prediction model to further examine 
whether they turned statistically significant, however, none were significant. Two-degree fractional 
polynomial terms were used to model non-linear associations between outcomes and continuous predictors 
[21]. Fractional polynomial parameters were also re-checked at this stage and re-estimated when necessary. 
The risk score is calculated as the log odds from the final prediction model with the selected predictors (and polynomials), and the predicted risk is derived from the log odds [18].
Model calibration was assessed by plotting the mean predicted probability against the mean observed 
proportion of cerebrovascular mortality by tenth of predicted risk. Model discrimination was assessed with 
the concordance statistic (C-statistic). A value of 0.50 represents no discrimination and 1.00 represents 
perfect discrimination. Internal validation of the model discrimination was assessed by calculating the 
bootstrap optimism-corrected c-statistic with 100 bootstrap replications.To facilitate model utilisation in clinical practice, the logistic regression equations were transformed 
into prognostic score charts. The coefficients in the logistic regression equation were multiplied by 50 and 
rounded to the nearest integer to obtain the prognostic score per predictor. Multiplication by 50 was chosen 
to ensure that a majority of the coefficients were close to being an integer, thereby minimizing the effects of 
rounding. The sum of all prognostic scores reflects patients’ probability of cerebrovascular mortality.
We used Stata V15.1 for all statistical analyses. This study was conducted and reported in line with 
the Transparent Reporting of a multivariate prediction model for Individual Prediction Diagnosis (TRIPOD) guidelines [22].
Results
Study participants
In our cohort, we analysed information on 3,054 patients with 89 cerebrovascular deaths within 2 years of initialisation of PD. The population characteristics measured at baseline for the study population are presented in Table 1.
Model development and model performanceAmong the 26 candidate predictors, 18 parameters from 11 predictors through 
backward elimination remained in the final model (Table 2). With optimism adjustment, 
the final prediction model was able to discriminate patients initialising PD with and without 
cerebrovascular mortality with a C statistic of 0.744 (95% confidence interval 0.699 to 
0.788). Good apparent calibration was presented as the agreement between the observed and predicted proportion of events (Fig. 1). Table 3 and Fig. 2 illustrate the risk prediction 
equations with real clinical examples.
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Table 1. Baseline Characteristics of study cohort. Binary variables are displayed as numbers (percentage) and continuous variables are displayed as median (interquartile) Candidate Predictors Derivation Cohort N 3,054 Cerebrovascular Deaths, n (%) 89 (2.9) Male Gender, n (%) 1,790 (58.6) Primary Glomerular Disease, n (%) 1,446 (47.3) Age, years 48.9 (38.0 to 59.0) Haemoglobin, g/L 88.0 (75.0 to 102.0) Packed cell volume  19.0 (2.3 to 27.5) Reticulocyte, %  34.9 (13.1 to 60.2) Phosphate, mg/dl 1.8 (1.4 to 2.2) Albumin, g/L 33.6 (29.7 to 37.8) Total iron binding capacity, μmol/L 45.0 (35.0 to 52.6) FeTIBC, mmol/L 25.0 (20.9 to 41.1) Creatinine, µmol/L 837.0 (633.0 to 1066.0) estimated Glomerular Filtration rate, mL/min/1.73 m2 4.8 (3.6 to 6.9) Transferrin, mg/dl 194.9 (119.9 to 399.4) Total protein, g/L 57.6 (52.0 to 63.0) Prealbumin, mg/L 294.0 (197.4 to 363.0) Total Cholesterol, mmol/L 4.4 (3.6 to 5.2) Low density lipoprotein, mmol/L 2.6 (1.8 to 3.4) Fasting glucose, mmol/L 4.9 (4.3 to 5.9) Sodium, mEq/L 140.0 (136.9 to 142.3) C-reaction protein, mg/dl 2.4 (1.0 to 5.3) Body mass index, kg/m2 22.7 (20.7 to 24.9) Systolic blood pressure, mmHg 145.0 (135.0 to 159.0) Diastolic blood pressure, mmHg 86.0 (80.0 to 95.0) Cerebrovascular diseases, n (%) 1,384 (45.3) Type 2 Diabetes, n (%) 449 (14.7) Taking antihypertensive treatment, n (%) 1257 (41.2)                                           
Table 2. Final multivariate analysis for cerebrovascular mortality risk within two years of initialisation of peritoneal dialysis
         Predictors Coefficient 95% Confidence Interval (BMI/10)^3 0.626533 (-0.030687 to 1.283753) Ln(BMI/10)*(BMI/10)^3 -0.475435 (-1.001754 to 0.050883) [(phosphate+0.9491628725516048)/10]^3 3.143257 (-22.169120 to 28.455630) [(phosphate+0.9491628725516048)/10]^3*Ln[(phosphate+0.9491628725516048)/10] 0.148686 (-41.275240 to 41.572610) [(total protein)/100]^-2 -0.032448 (-1.046089 to 0.981193) [(total protein)/100]^-2*Ln[(total protein)/100] 0.044152 (-0.687377 t0 0.775681) [(total cholesterol+1.673428429186277)/10]^0.5 -4.935679 (-20.685340 to 10.813990) [(total cholesterol+1.673428429186277)/10]^0.5*Ln[(total cholesterol+1.673428429186277)/10] 3.353445 (-7.293830 to 14.000720) (sodium/100)^3 8.310844 (-6.262589 to 22.884280) (sodium/100)^3*Ln(sodium/100) -14.405770 (-37.254140 to 8.442614) (systolic blood pressure/100)^-2 -3.144864 (-6.204293 to -0.085436) (systolic blood pressure/100)^-2*Ln(systolic blood pressure/100) -8.223230 (-14.442550 to -2.003909) (diastolic blood pressure/100)^3 0.651553 (-1.649131 to 2.952236) (diastolic blood pressure/100)^3*ln(diastolic blood pressure/100) -3.360246 (-10.423590 to 3.703100) Age 0.007272 (-0.013218 to 0.027763) Albumin -0.058305 (-0.103438 to -0.013172) Low density lipoprotein cholesterol -0.104797 (-0.317004 to 0.107411) Glucose 0.024396 (-0.056247 to 0.105039) Constant -6.785156 (-31.849070 to 18.278760)                         
Fig. 1. Calibration of the prediction model—the 
observed 2-year probability of Cerebrovascular 
mortality by tenths of model-predicted probability.
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DiscussionWe have developed and validated a new risk prediction model to estimate the individual level absolute risk of cerebrovascular mortality during the 
first 2 years of initialisation of PD in a representative Chinese sample of patients. Both good model calibration and discrimination, with a C statistic of greater 
than 0.70 were found in the final risk prediction model.This newly developed risk prediction model has several advantages for its application in most developing countries. This risk prediction model is based on individual level absolute risk developed 
and validated in a prospective cohort. It is derived from reliable clinical measurements that are usually performed among patients initialising PD, implying that it can be readily applied in routine clinical practice.  The model 
is amenable to further external validation in many regions and countries that operate routine PD care.The methods used to derive and validate the model are close to those for other risk 
prediction models developed from the CPRD and QResearch databases [21, 23]. The data used in this study were the largest dataset used for risk algorithms among patients 
initialising PD care. As the only PD registry data, HPRD includes all patients initialising PD care in Henan who are followed up for their lifetime; therefore, responder bias and selection bias were minimised in this study. Being located in Henan, the province with the second largest population in China, the population used in this study is likely to be a nationally representative sample.Our study had some limitations. First, patients in this study were distinctively different 
from European ESRD patients in some characteristics, e.g. younger age, lower prevalence 
Fig. 2. Graphical illustration of cerebrovascular 
mortality prognostic score for the clinical example.
 
Table 3. Prognostic score chart for predicting cerebrovascular mortality among incident peritoneal dialysis 
patients. Clinical example: 52 years old, 21.87 kg/m2 of body mass index, 1.53 mg/dl phosphate, 2.45g/L 
total protein, 2.45mmol/L total cholesterol, 124 mEq/L sodium, 136 mmHg systolic blood pressure, 84 
mmHg diastolic blood pressure, 3.05mmol/L low-density lipoprotein cholesterol and 7.1 mmol/L glucoseFP term, indicates fractional polynomial term     Predictors  Description  Value  Score  Body mass index-FP term 1  (BMI/10)^3  13.623  680  Body mass index-FP term 2  Ln(BMI/10)*(BMI/10)^3  -10.590  -529  Phosphate-FP term 1  [(phosphate+0.9491628725516048)/10]^3  0.048  2  Phosphate- FP term 2  [(phosphate+0.9491628725516048)/10]^3*Ln[(phosphate +0.9491628725516048)/10]  -0.003  0  Total protein- FP term 1  [(total protein)/1 0]^-2  -0.084  -4  Total protein FP term 2  [(total protein)/100]^-2*Ln[(total protein)/100]  -0.054  -3  Total cholesterol- FP term 1  [(total cholesterol+1.673428429186277)/10]^0.5  -3.169  -158  Total cholesterol- FP term 2  [(total cholesterol+1.673428429186277)/10]^0.5*Ln[(total cholesterol+1.673428429186277)/10]  -1.908  -95  Sodium- FP term 1  (sodium/100)^3  15.846  792  Sodium FP term 2  (sodium/100)^3*Ln(sodium/100)  -5.908  -295  Systolic blood pressure-FP term 1  (systolic blood pressure/100)^-2  -1.700  -85  Systolic blood pressure- FP term 2  (systolic blood pressure/100)^-2*Ln(systolic blood pressure/100)  -1.367  -68  Diastolic blood pressure- FP term 1  (diastolic blood pressure/100)^3  0.386  19  Diastolic blood pressure- FP term 2  (diastolic blood pressure/100)^3*ln(diastolic blood pressure/100)  0.347  17  Age  (BMI/10)^3  0.378  19  Albumin  Constant=1  -1.166  -58  Low density lipoprotein cholesterol    -0.320  -16  Glucose    0.173  9  Constant    -6.785  -339    Sum Score  -114  Predicted probability of cerebrovascular hospitalisation 9.3%   
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of comorbidities, lower percentage receiving treatment and lower BMI.  This suggests that 
more adjustments in these confounders might be needed when applying this risk prediction 
model into external ESRD populations, especially European patients with ESRD [4]. Second, some conventional cardiovascular risk factors, such as lifestyle risk factors (i.e. smoking) and previous health status information were not accessible in this study. Third, the relatively high volume of missing values in some variables, e.g. albumin and phosphate might potentially have 
impacted upon the extrapolation of the risk algorithm especially in the external population, this impact should have been reduced through the development of the risk prediction model 
using imputed datasets. Fourth, although patients in some developing regions/countries where access to, or the validity of, prior health records on cerebrovascular risk factors 
and multi-comorbidity are restricted might benefit from this risk prediction tool, further 
external validation in other distinctively different cohorts would still be warranted. Fifth, the 
distinctive threshold of absolute risk to define “high-risk” ESRD patients was not suggested 
in our study, as this definition would need to balance cerebrovascular mortality risks and 
clinical benefits for patients and analyse cost effectiveness, which exceeded this study scope. 
Finally, as cause of death can sometimes be uncertain, leading to outcome misclassification, 
future external validation studies are further warranted in other populations.
All potential clinical measurements in HPDR were reviewed by a review panel with 
5 independent clinicians and considered as candidate predictors following a consensus 
process (agreed by ≥3 clinicians). This prediction model is different from currently existing 
risk algorithms derived in developed countries, through the exclusion of comorbidities, 
inconsideration of the difficulties in accessing and validating such data that are not routinely 
recorded in the under-developed primary care system in China.
The majority of predictors included in the risk algorithm are reliable and accurate clinical 
measurements [10] that are routinely collected at the time of entry into PD and accessible 
across Chinese PD clinical centres [24]. Moreover, the risk of recall bias in this study was 
potentially low with the limited use of self-reported information. Based on these, this risk 
prediction model can be readily validated within other external cohort or registry datasets.
Conclusion
Our study has developed a tool that predicts the 2-year risk of cerebrovascular mortality among incident peritoneal dialysis patients. Our prediction model has two important implications for clinical practice. First it can be used to screen populations at high risk for cerebrovascular mortality on initiating PD. The algorithm is based on readily accessible 
clinical data recorded in the PD registration database which can be reviewed by the PD/
ESRD management team. It can be readily integrated into a PD registration computer system or an application for a handheld device for easy use. Secondly, this prediction tool could be used to establish treatment thresholds in PD clinical care through consensus development of national guidance.
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